CLINICAL TRIALS PROFILE FOR SITRAVATINIB

Clinical Trials for Sitravatinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02219711 ↗	Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer	Active, not recruiting	Mirati Therapeutics Inc.	Phase 1	MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.
NCT02664935 ↗	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Active, not recruiting	AstraZeneca	Phase 2	The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.
NCT02664935 ↗	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Active, not recruiting	Cancer Research UK	Phase 2	The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.
NCT02664935 ↗	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Active, not recruiting	Experimental Cancer Medicine Centre Network	Phase 2	The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.
NCT02664935 ↗	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Active, not recruiting	Experimental Cancer Medicine Centres	Phase 2	The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.
NCT02664935 ↗	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Active, not recruiting	Mirati Therapeutics Inc.	Phase 2	The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.

Clinical Trial Conditions for Sitravatinib

Condition Name

Condition Name
Intervention	Trials
Healthy Adults	3
Clear Cell Renal Cell Carcinoma	2
Hepatocellular Carcinoma	2
Carcinoma, Non-Small-Cell Lung	2

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoma	11
Carcinoma, Non-Small-Cell Lung	7
Lung Neoplasms	5
Carcinoma, Renal Cell	5

Clinical Trial Locations for Sitravatinib

Trials by Country

Trials by Country
Location	Trials
United States	116
China	45
Spain	9
Australia	9
Netherlands	8

Trials by US State

Trials by US State
Location	Trials
Texas	14
California	6
Ohio	5
Nebraska	4
Missouri	4

Clinical Trial Progress for Sitravatinib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	1
Phase 2	18

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	10
Active, not recruiting	10

Clinical Trial Sponsors for Sitravatinib

Sponsor Name

Sponsor Name
Sponsor	Trials
Mirati Therapeutics Inc.	20
BeiGene	9
Fudan University	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	32
Other	23
NIH	1